Brief: XtalPi & PharmaEngine Hit Milestone as PRMT5 Inhibitor PEP08 Gets Trial Nod
09/09/2025 13:44
Sept 9 (Reuters) - XtalPi Holdings Ltd 2228.HK: XTALPI AI DRUG DISCOVERY COLLABORATION REACHES MILESTONE AS PHARMAENGINE'S NOVEL PRMT5 INHIBITOR PEP08 RECEIVES CLINICAL TRIAL APPROVALS Source text: ID:nPn2myz5ka Further company coverage: 2228.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on XtalPi Holdings
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Hong Kong-listed XtalPi climbs as chairman buys shares
Brief: XtalPi Says Chairman Purchases 3.8 MLN Shares From Oct 7 To Oct 15
Brief: XtalPi Reports Chairman Wen Shuhao Purchases 1.3 Million Shares on Oct 7
XtalPi hits near 4-month high as chairman plans to buy shares